home icon user icon
Welcome to International Network for Natural Sciences | INNS Pub.
Home My Account
Submit Manuscript
double_slash
breadcumb_bg

Drug resistance mechanism and therapeutic strategies in Mycobacterium abscessus

Paper Details

Research Paper 06/10/2024
Views (56) Download (6)
current_issue_feature_image
publication_file

Drug resistance mechanism and therapeutic strategies in Mycobacterium abscessus

Debobrata Sharma, Yeasin Arafat, Promi Dewan, M.M. Sultan Mahmud, Shamim Ahmed, Md Motaher Hossain, Md Abdulla Al Jubayed, B. M. Mahmudul Hasan
Int. J. Biosci.25( 4), 96-104, October 2024.
Certificate: IJB 2024 [Generate Certificate]
Key: AntibioticsInfectionsMechanismsMycobacterium abscessusResistanceTherapeutic

Abstract

Considering its resistance mechanisms, Mycobacterium abscessus (Mab) is a major threat to current therapeutic techniques since it is one of the primary causes of serious respiratory infections in immunocompromised persons. The chemotherapeutic choices for infections triggered by Mycobacterium abscessus have become scarce due to its innate and acquired resistance to regularly administered antibiotics. Therefore, for efficient therapy, it is imperative to understand both intrinsic and acquired resistant to antibiotics in Mab. In this current review, we provide recent updates on the mechanisms of both intrinsic and acquired resistant to antibiotics and treatment efficacy in Mab. Thus, a thorough comprehension of the mechanisms underlying drug resistance and the therapeutic effectiveness of antibiotics against Mab can yield novel suggestions for enhancing treatment results, lowering mortality, averting drug resistance, and stopping Mab transmission. Furthermore, it will aid in the development of new antibiotics for Mab as well as quick molecular diagnostic tools.

VIEWS 25
Cover PDF

Abdelaal HF, Chan ED, Young L, Baldwin SL, Coler RN. 2022. Mycobacterium abscessus: it’s complex. Microorganisms 10, 1454. http://dx.doi.org/10.3390/microorganisms10071454.

Alcaide F, Pfyffer GE, Telenti A. 1997. Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrobial Agents and Chemotherapy 41(10), 2270-2273. http://dx.doi.org/10.1128/AAC.41.10.2270.

Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. 2015. Molecular mechanisms of antibiotic resistance. Nature Reviews Microbiology 13(1), 42. http://dx.doi.org/10.1038/nrmicro3380.

Brown-Elliott BA, Wallace RJ. 2002. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clinical Microbiology Reviews 15(4), 716-746. http://dx.doi.org/10.1128/CMR.15.4.716-746.2002.

Chen J, Zhao L, Mao Y, Ye M, Guo Q, Zhang Y, Xu L, Zhang Z, Li B, Chu H. 2019. Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease. Frontiers in Microbiology 10, 1977. http://dx.doi.org/10.3389/fmicb.2019.01977.

Colombo RE, Olivier KN. 2008. Diagnosis and treatment of infections caused by rapidly growing mycobacteria. In Seminars in Respiratory and Critical Care Medicine 29, 577–588. http://dx.doi.org/10.1055/s-0028-1085709.

Cowman S, Van Ingen J, Griffith DE, Loebinger MR. 2019. Non-tuberculous mycobacterial pulmonary disease. European Respiratory Journal 54(1), 1900250. http://dx.doi.org/10.1183/13993003.00250-2019.

Cristancho-Rojas C, Varley CD, Lara SC, Kherabi Y, Henkle E, Winthrop KL. 2024. Epidemiology of Mycobacterium abscessus. Clinical Microbiology and Infection 30, 712-717. http://dx.doi.org/10.1016/j.cmi.2023.08.035.

Daffé, M, Draper P. 1997. The envelope layers of mycobacteria with reference to their pathogenicity. In advances in Microbial Physiology 39, 131-203. http://dx.doi.org/10.1016/s0065-2911(08)60016-8.

Dautzenberg B, Truffot C, Legris S, Meyohas MC, Berlie HC, Mercat A, Chevret S, Grosset J. 1991. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. American Review Respiratory Disease 144, 564-569. http://dx.doi.org/10.1164/ajrccm/144.3_Pt_1.564.

Dupont C, Viljoen A, Dubar F, Blaise M, Bernut A, Pawlik A, Bouchier C, Brosch R, Guérardel Y, Lelièvre J, Ballell L. 2016. A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus. Molecular Microbiology 101(3), 515-529. http://dx.doi.org/10.1111/mmi.13406.

Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. American Journal of Respiratory and Critical Care Medicine 175(4), 367-416. http://dx.doi.org/10.1164/rccm.200604-571ST.

Guillemin I, Jarlier V, Cambau E. 1998. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrobial Agents and Chemotherapy 42(8), 2084-2088. http://dx.doi.org/10.1128/AAC.42.8.2084.

Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P. 2017. British thoracic Society guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Respiratory Research 4(1), e000242. http://dx.doi.org/10.1136/bmjresp-2017-000242.

Kerr ID, Reynolds ED, Cove JH. 2005. ABC proteins and antibiotic drug resistance: is it all about transport?. Biochemical Society Transactions 33, 5. http://dx.doi.org/10.1042/BST20051000.

Kothavade RJ, Dhurat RS, Mishra SN, Kothavade UR. 2013. Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria. European Journal of Clinical Microbiology & Infectious Diseases 32(2), 161-188. http://dx.doi.org/10.1007/s10096-012-1766-8.

Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R. 2019. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. European Respiratory Journal 54(1), 1801991. http://dx.doi.org/10.1183/13993003.01991-2018.

Leard LE, Holm AM, Valapour M, Glanville AR, Attawar MAversa S. 2021. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation J Heart Lung Transplant 40, 1349-1379. http://dx.doi.org/10.1016/j.healun.2021.07.005.

Louw GE, Warren RM, Van Pittius NG, McEvoy CR, Van Helden PD, Victor TC. 2009. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrobial Agents and Chemotherapy 53(8), 3181-3189. http://dx.doi.org/10.1128/AAC.01577-08.

Luthra S, Rominski A, Sander P. 2018. The role of antibiotic-target-modifying and antibiotic-modifying enzymes in Mycobacterium abscessus drug resistance. Frontiers in Microbiology 9, 2179. http://dx.doi.org/10.3389/fmicb.2018.02179.

Martin C, Timm J, Rauzier J, Gomez-Lus R, Davies J, Gicquel B. 1990. Transposition of an antibiotic resistance element in mycobacteria. Nature 345(6277), 739. http://dx.doi.org/10.1038/345739a0.

Maxson S, Schutze GE, Jacobs RF. 1994. Mycobacterium abscessus osteomyelitis: treatment with clarithromycin. Infectious Diseases in Clinical Practice 3(3), 203-206. http://dx.doi.org/

Moore M, Frerichs JB. 1953. An Unusual Acid-Fast Infection of the Knee with Subcutaneous, Abscess-Like Lesions of the Gluteal Region: Report of a Case with a Study of the Organism, Mycobacterium abscessus, n. sp. Journal of Investigative Dermatology 20(2), 133-69. http://dx.doi.org/10.1038/jid.1953.18.

Mudde SE, Schildkraut JA, Ammerman NC, de Vogel CP, de Steenwinkel JE, van Ingen J, Bax HI. 2022. Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: the potential role of efflux pumps. Journal of Global Antimicrobial Resistance 31, 345-52. http://dx.doi.org/10.1016/j.jgar.2022.10.015.

Musser JM. 1995. Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clinical Microbiology Reviews 8(4), 496-514. http://dx.doi.org/10.1128/CMR.8.4.496.

Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. 2012. Mycobacterium abscessus: a new antibiotic nightmare. Journal of antimicrobial chemotherapy  67(4), 810-818. http://dx.doi.org/10.1093/jac/dkr578.

Nguyen L, Thompson CJ. 2006. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends in Microbiology 14(7), 304-312. http://dx.doi.org/10.1016/j.tim.2006.05.005.

Paulsen IT, Brown MH, Skurray RA. 1996. Proton-dependent multidrug efflux systems. Microbiology Molecular Biology Review 60(4), 575-608. http://dx.doi.org/10.1128/mr.60.4.575-608.1996.

Poehlsgaard J, Douthwaite S. 2003. Macrolide antibiotic interaction and resistance on the bacterial ribosome. Current Opinion in Investigational Drugs 4(2), 140-148.

Prammananan T, Sander P, Brown BA, Frischkorn K, Onyi GO, Zhang Y, Böttger EC, Wallace Jr RJ. 1998. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. Journal of Infectious Diseases 177(6), 1573-1581. http://dx.doi.org/10.1086/515328.

Qvist T, Taylor-Robinson D, Waldmann E, Olesen HV, Hansen CR Mathiesen IH. 2016. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis 15, 380-385. http://dx.doi.org/10.1016/j.jcf.2015.09.007.

Richard M, Gutiérrez AV, Viljoen A, Rodriguez-Rincon D, Roquet-Baneres F, Blaise M, Everall I, Parkhill J, Floto RA, Kremer L. 2019. Mutations in the MAB_2299c TetR regulator confer cross-resistance to clofazimine and bedaquiline in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy 63(1), e01316-18. http://dx.doi.org/10.1128/AAC.01316-18.

Ripoll F, Pasek S, Schenowitz C, Dossat C, Barbe V, Rottman M, Macheras E, Heym B, Herrmann JL, Daffé M, Brosch R. 2009. Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus. PloS One 4(6), e5660. http://dx.doi.org/10.1371/journal.pone.0005660.

Rominski A, Roditscheff A, Selchow P, Böttger EC, Sander P. 2017a. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. Journal of Antimicrobial Chemotherapy 72(2), 376-384. http://dx.doi.org/10.1093/jac/dkw466.

Rominski A, Selchow P, Becker K, Brülle JK, Dal Molin M, Sander P. 2017b. Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes. Journal of Antimicrobial Chemotherapy 72(8), 2191-2200. http://dx.doi.org/10.1093/jac/dkx125.

Rossi ED, Aínsa JA, Riccardi G. 2006. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiology Reviews 30(1), 36-52. http://dx.doi.org/10.1111/j.1574-6976.2005.00002.x.

Ruis C, Bryant JM, Bell SC, Thomson R, Davidson RM, Hasan NA. 2021. Dissemination of Mycobacterium abscessus via global transmission networks. Nature Microbiololgy 6, 1279-1288. http://dx.doi.org/0.1038/s41564-021-00963-3.

Ryu YJ, Koh WJ, Daley CL. 2016. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians’ perspectives. Tuberculosis and Respiratory Diseases 79(2), 74-84. http://dx.doi.org/10.4046/trd.2016.79.2.74.

Sander P, Böttger E. 1999. Mycobacteria: genetics of resistance and implications for treatment. Chemotherapy 45(2), 95-108. http://dx.doi.org/10.1159/000007171.

Shakil S, Khan R, Zarrilli R, Khan AU. 2008. Aminoglycosides versus bacteria-a description of the action, resistance mechanism, and nosocomial battleground. Journal of Biomedical Science 15(1), 5-14. http://dx.doi.org/10.1007/s11373-007-9194-y.

Stout JE, Koh WJ, Yew WW. 2016. Update on pulmonary disease due to non-tuberculous mycobacteria. International Journal of Infectious Diseases 45, 123-34. http://dx.doi.org/10.1016/j.ijid.2016.03.006.

Strnad L, Winthrop KL. 2018. Treatment of Mycobacterium abscessus complex. InSeminars in Respiratory and Critical Care Medicine 39, 362-376. http://dx.doi.org/10.1055/s-0038-1651494.

Victoria L, Gupta A, Gómez JL, Robledo J. 2021. Mycobacterium abscessus complex: a review of recent developments in an emerging pathogen. Frontiers in Cellular and Infection Microbiology 11, 659997. http://dx.doi.org/10.3389/fcimb.2021.659997.

Zomer D, van Ingen J, Hofland R, Akkerman OW, Altenburg J, Bakker M, Bannier MA, Conemans LH, Gulmans VA, Heijerman HG, Hoek RA. 2023. Epidemiology and management of nontuberculous mycobacterial disease in people with cystic fibrosis, the Netherlands. Journal of Cystic Fibrosis 22(2), 327-333. http://dx.doi.org/10.1016/j.jcf.2022.10.009.

Submit Manuscript